Navigation Links
New Enhancements to Access MediQuip's Partners In Focus Online Web Portal Delivers Next Generation, Market-Leading Communication Platform to Surgical Facilities
Date:9/19/2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, 2014 ... weight are at risk later in life of having smaller, ... for heart disease, according to a pair of new studies. ... disadvantages, researchers in both studies -- published online Sept. 1 ... be overcome. Education appeared to negate the potential harmful ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... Magee Rehabilitation Hospital returns on September 19 at The ... Hill, Pennsylvania. Over the past 25 years, the Classic, ... more than $12 million for programs and services designed ... at Magee Rehabilitation Hospital. , “The Segal Classic ...
(Date:9/2/2014)... 2014 National law firm, ... has filed an application for attorneys’ fees and ... action litigation brought over Flushmate flushing mechanisms. In ... Counsel in this litigation includes Birka-White Law Offices; ... Partners, LLP; Levin Fishbein, Sedran & Berman, LLP; ...
(Date:9/2/2014)... Lseat.com is one of the most popular suppliers of useful ... items; no professional installation is required. Customers do not need ... over the cars’ seats. That can save plenty of time ... various kinds of practical covers. , In addition, it ... seat covers . Also, the company has launched a special ...
(Date:9/2/2014)... 2014 The global market for peripheral ... by 2020, growing at an estimated CAGR of 7.2% ... by Grand View Research, Inc. Peripheral vascular devices such ... are used for treating peripheral arterial or coronary arterial ... in arteries. These devices are used to decrease the ...
Breaking Medicine News(10 mins):Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3Health News:High Quality 1997-2006 JEEP Wrangler TJ Leather Seat Covers From Popular Supplier Lseat.com 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5
... from the Journal of Traumatic Stress finds ... who are happily married, communicating frequently with one,s spouse ... the development of posttraumatic stress disorder (PTSD) symptoms after ... male Army soldiers who returned from military deployment within ...
... (BUSM) researchers have found that Gabapentin, (trade name Neurontin) ... and biopolar disease in older and elderly patients, seems ... to experience orgasm, than previously reported. This study ... Journal of Geriatric Pharmacotherapy . Anticonvulsants are the ...
... , THURSDAY, June 2 (HealthDay News) -- People ... hospitalization are more than twice as likely to be readmitted ... a new study has found. The finding suggests that ... patients, according to the researchers, who were to present the ...
... , THURSDAY, June 2 (HealthDay News) -- Noisy operating ... site infections, new study findings suggest. In the ... Journal of Surgery , the Swiss researchers also said these ... costly hospital stays. "SSIs lead to patients spending up ...
... an investigational vaccine made from their own frozen immune ... with it, according to data being presented by researchers ... 2011 American Society of Clinical Oncology annual meeting in ... In an exploratory, multi-institutional analysis, researchers administered the ...
... By Kathleen Doheny HealthDay Reporter , ... that low-carbohydrate diets, with regular exercise as part of ... some experts have feared. "It,s pretty clear low-carb ... J. Stewart, director of clinical and research exercise physiology ...
Cached Medicine News:Health News:Letters from home may help prevent post-traumatic stress disorder in happily married soldiers 2Health News:Emergency Care May Be Key to Hospital Readmissions 2Health News:Noisy ORs Linked to Raised Risk of Surgical Site Infection 2Health News:ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 3
(Date:9/2/2014)... 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Drug Administration (FDA) has granted orphan drug status to ... "The FDA Office of Orphan Products Development ... to identify and designate drug candidates that could potentially ... development of such products," said Craig M. Audet ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... -- Cepheid (NASDAQ: CPHD) announced today the release of ... test for rapid, accurate and reliable determination of ... infection. The test will be marketed as a ... In Vitro Diagnostic Medical Devices, bringing the ... XC runs on Cepheid,s GeneXpert ® System, ...
Breaking Medicine Technology:Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 2Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 4
... USCAP MeetingSOUTH SAN FRANCISCO, Calif., March 13 Rigel ... the enrollment of the first patient in a Phase ... patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). ... the efficacy of R788, an orally bio-available Syk kinase ...
... Phase II Study Published in The Lancet of Fast-Tracked ... Minor Bleeding and was Well Tolerated When Given With ... a Schering-Plough Corporation (NYSE: SGP ) Phase ... receptor antagonist (TRA), were published today in The ...
Cached Medicine Technology:Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
... The Finnpipette BioControl multichannel ... as the single channel model. ... all seven multichannel and five ... Both pipettes have a recharge ...
... solution and best value in high performance ... and ultra lightweight design reduce hand fatigue ... long, lever tip ejector , Color coding ... tips or for greater performance use Hamilton ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
Medicine Products: